Cuijun Hao^1-6#, Tianhua Hou^1-5#, Fei Wang^1-5, Rui Wang⁶, Yang Hong⁶, Xiaoying Li⁶, Meng Ning^1-5, Yingwu Liu^1-5

Abstract

Purpose: To investigate the efficacy of atorvastatin in the treatment of atherosclerotic cardiovascular disease (ASCVD) Methods: A total of 158 patients who underwent coronary angiography in the Department of Cardiology, First Affiliated Hospital of Hebei North University, China were divided into acute myocardial infarction (AMI, n = 42), unstable angina pectoris (UAP, n = 70), and control (n = 46) groups. Atorvastatin (40 mg) was administered to the patients in AMI and UAP groups for 40 days. Triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, phospholipase A2 (PLA2), YKL40, and clinical efficacy were evaluated after treatment. Results: Acute myocardial infarction group (AMI) had significantly higher TC, LDL-C, non-HDL-C, PLA2, and YKL40 levels compared to UAP and control (p < 0.05). Also, HDL-C, TG, and TG/HDL-C were significantly higher in AMI and UAP compared to control group (p < 0.05). In coronary heart disease, TG/HDL-C had the highest sensitivity, and LDL-C had the highest specificity. Furthermore, TC, LDL-C, and TG significantly decreased in both AMI and UAP groups (p < 0.05), while HDL-C remained unchanged (p > 0.05). Conclusion: Atorvastatin effectively improves lipid profiles in ASCVD patients, and markers such as PLA2 and YKL40 effectively predict ASCVD risk. Further larger-scale, long-term studies are needed to validate the effectiveness of combining lipid and inflammatory biomarkers for ASCVD risk prediction and management.